Medulloblastoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Medulloblastoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes https://clinicaltrials.eu/trial/comparing-two-treatment-regimens-with-drug-combination-for-newly-diagnosed-low-risk-medulloblastoma-to-evaluate-cognitive-function-outcomes/ Wed, 29 Apr 2026 15:06:28 +0000 https://clinicaltrials.eu/trial/comparing-two-treatment-regimens-with-drug-combination-for-newly-diagnosed-low-risk-medulloblastoma-to-evaluate-cognitive-function-outcomes/ This clinical trial focuses on studying medulloblastoma, specifically the non-metastatic, SHH-activated type in young patients. Medulloblastoma is a type of brain tumor that typically develops in children. The study aims to compare brain function outcomes between two different treatment approaches.

The treatment involves several chemotherapy medications including methotrexate, etoposide, cyclophosphamide, carboplatin, vincristine, cisplatin, and thiotepa. These medications will be given through different methods, including directly into the bloodstream through a vein and, in some cases, directly into areas around the brain.

The study will track how well children’s thinking and learning abilities develop over time after receiving treatment. Doctors will measure these abilities through various tests when the treatment starts and continue monitoring for several years afterward. They will also check for any hearing problems and changes in brain tissue that might occur as a result of the treatment.

]]> Study on the Safety and Effectiveness of Methotrexate and Drug Combination for Children and Young Adults with High-Risk Metastatic Medulloblastoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-methotrexate-and-drug-combination-for-children-and-young-adults-with-high-risk-metastatic-medulloblastoma/ Wed, 29 Apr 2026 15:03:01 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-methotrexate-and-drug-combination-for-children-and-young-adults-with-high-risk-metastatic-medulloblastoma/ This clinical trial is focused on studying the safety and effectiveness of chemotherapy combined with radiation therapy for patients with metastatic medulloblastoma and other similar types of brain tumors known as embryonal tumors. These are aggressive tumors that can spread to other parts of the brain and spinal cord. The study involves several chemotherapy medications, including Methotrexate, Carboplatin, Lomustine, Cyclophosphamide, Etoposide, Thiotepa, and Vinorelbine. These medications are used to kill cancer cells or stop them from growing and are administered either through an infusion into a vein or taken orally as a capsule.

The purpose of the study is to evaluate the safety of using both standard and high doses of these chemotherapy drugs along with radiation therapy that targets the brain and spinal cord. The study is designed for children and young adults who have been newly diagnosed with high-risk medulloblastoma or other embryonal tumors. Participants will receive treatment over a period of time, and their health will be closely monitored to assess any side effects and the overall effectiveness of the treatment.

Throughout the study, researchers will track the participants’ progress, including how long they live without the disease getting worse, known as progression-free survival, and their overall survival. The study will also look at any changes in neurological and psychological health, as well as any other health issues that may arise as a result of the treatment. The goal is to find the best way to treat these challenging types of brain tumors while ensuring the safety and well-being of the participants.

]]> Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination https://clinicaltrials.eu/trial/study-on-medulloblastoma-treatment-in-children-aged-3-5-using-carboplatin-and-drug-combination/ Wed, 29 Apr 2026 14:59:02 +0000 https://clinicaltrials.eu/trial/study-on-medulloblastoma-treatment-in-children-aged-3-5-using-carboplatin-and-drug-combination/ This clinical trial is focused on studying a type of brain cancer called medulloblastoma, which occurs in children. The study aims to explore different treatment approaches for children with various risk levels of this disease. The treatments being tested include a combination of radiation therapy and chemotherapy, which involves using drugs to kill cancer cells. The chemotherapy drugs used in this study are carboplatin, methotrexate, cisplatin, cyclophosphamide, doxorubicin hydrochloride, vinblastine sulfate, vincristine, and lomustine. These drugs are administered in different forms, such as solutions for infusion or injection, and capsules.

The purpose of the study is to determine the effectiveness of these treatments in improving the survival rates of children with medulloblastoma. The study is divided into different groups based on the risk level and biological characteristics of the cancer. For example, one group will receive a combination of radiation and chemotherapy, while another group will receive chemotherapy alone. The study will also look at the impact of these treatments on the quality of life and any side effects experienced by the participants.

Participants in the study will receive treatment over a period of time, with regular follow-ups to monitor their progress. The study will assess the event-free survival, which means the length of time the participants remain free from cancer-related events, such as recurrence or progression of the disease. The study will also evaluate overall survival, which is the length of time the participants live after starting the treatment. By comparing the outcomes of different treatment approaches, the study aims to find the most effective way to treat medulloblastoma in children.

]]> Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine https://clinicaltrials.eu/trial/study-on-high-risk-medulloblastoma-treatment-with-thiotepa-and-drug-combination-for-patients-over-3-years/ Wed, 29 Apr 2026 14:58:10 +0000 https://clinicaltrials.eu/trial/study-on-high-risk-medulloblastoma-treatment-with-thiotepa-and-drug-combination-for-patients-over-3-years/ This clinical trial focuses on treating high-risk medulloblastoma, which is a type of brain tumor. The study specifically targets patients who have either sonic hedgehog (SHH) subgroup or non-SHH/non-WNT (Groups 3 and 4) medulloblastoma with additional high-risk features. The treatment involves multiple medications including carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, and vincristine sulfate.

The purpose of this study is to determine if treatment outcomes can be improved by using either specialized radiation therapy called hyperfractionated-accelerated radiotherapy or high-dose therapy with thiotepa, compared to standard radiation therapy. The study will also evaluate the effectiveness of different maintenance chemotherapy treatments.

The treatment plan combines various methods of drug administration, with some medications given through a vein (intravenous route) and others taken by mouth (oral route). The medications will be given according to specific schedules and doses determined by the study protocol. The study will track how well patients respond to treatment by measuring how long they remain free of disease progression and their overall survival.

]]> Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months – 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors https://clinicaltrials.eu/trial/study-on-ribociclib-topotecan-and-temozolomide-for-children-and-young-adults-12-months-21-years-with-relapsed-or-refractory-neuroblastoma-and-solid-tumors/ Wed, 29 Apr 2026 14:30:04 +0000 https://clinicaltrials.eu/trial/study-on-ribociclib-topotecan-and-temozolomide-for-children-and-young-adults-12-months-21-years-with-relapsed-or-refractory-neuroblastoma-and-solid-tumors/ This clinical trial is focused on studying the treatment of relapsed or refractory neuroblastoma and other solid tumors in children and young adults aged 12 months to 21 years. Neuroblastoma is a type of cancer that forms in certain types of nerve tissue. The study will use a combination of medications, including ribociclib (also known by its code name LEE011), temozolomide, and topotecan hydrochloride. These medications are being tested together to see if they can effectively treat these types of cancers.

The purpose of the study is to assess the safety and effectiveness of this combination of drugs. The study is divided into two phases. In the first phase, researchers will determine the best dose of ribociclib to use with the other medications. In the second phase, the study will further evaluate how well this combination works in treating neuroblastoma compared to a placebo. Participants will receive the medications either orally or through intravenous infusion, depending on the specific drug.

Throughout the study, participants will be closely monitored for any side effects and to see how their tumors respond to the treatment. The study aims to find the most effective and safe way to use these medications together to help treat these challenging cancers in young patients. The trial is expected to continue until 2029, allowing researchers to gather comprehensive data on the treatment’s impact.

]]> Study on Preventing Hypothyroidism in Patients with Medulloblastoma and Pediatric Lymphoma Using Levothyroxine During Radiation Therapy https://clinicaltrials.eu/trial/study-on-preventing-hypothyroidism-in-patients-with-medulloblastoma-and-pediatric-lymphoma-using-levothyroxine-during-radiation-therapy/ Wed, 29 Apr 2026 14:29:03 +0000 https://clinicaltrials.eu/trial/study-on-preventing-hypothyroidism-in-patients-with-medulloblastoma-and-pediatric-lymphoma-using-levothyroxine-during-radiation-therapy/ This clinical trial is focused on studying the effects of radiation therapy on the thyroid gland in patients with medulloblastoma, Hodgkin lymphoma, and non-Hodgkin lymphoma. These are types of cancers that may require radiation treatment near the thyroid gland, which can sometimes lead to a condition called hypothyroidism. Hypothyroidism occurs when the thyroid gland does not produce enough hormones, which can affect various body functions.

The study aims to find out if using a medication called Levothyroxine can help reduce the risk of developing hypothyroidism after radiation therapy. Levothyroxine is a medication that helps to replace or supplement the hormones that the thyroid gland usually produces. In this study, some patients will receive Levothyroxine during their radiation treatment, while others will not, to see if it makes a difference in preventing hypothyroidism.

Participants in the study will be monitored for three years after their radiation therapy to check for signs of hypothyroidism. The goal is to determine if Levothyroxine can help protect the thyroid gland during radiation treatment and improve the long-term health of patients with these types of cancer. This research is important for finding better ways to manage the side effects of cancer treatments and improve the quality of life for patients.

]]> Study on Personalized Treatment for Post-Pubertal Patients with Newly Diagnosed Medulloblastoma Using Sonidegib, Cisplatin, Lomustine, and Vincristine https://clinicaltrials.eu/trial/study-on-personalized-treatment-for-post-pubertal-patients-with-newly-diagnosed-medulloblastoma-using-sonidegib-cisplatin-lomustine-and-vincristine/ Wed, 29 Apr 2026 14:27:49 +0000 https://clinicaltrials.eu/trial/study-on-personalized-treatment-for-post-pubertal-patients-with-newly-diagnosed-medulloblastoma-using-sonidegib-cisplatin-lomustine-and-vincristine/ This clinical trial is focused on studying a type of brain cancer called medulloblastoma, which is newly diagnosed in patients who are post-pubertal or adults. The study aims to explore a personalized treatment approach based on the patient’s age and specific characteristics of the tumor. The treatment involves adjusting the doses of radiation therapy and chemotherapy and introducing an investigative drug called sonidegib. The trial will compare this personalized treatment to the standard therapy in a subgroup of patients with a specific type of medulloblastoma known as SHH-activated.

Participants in the study will receive different medications, including cisplatin, lomustine, and vincristine, alongside the investigative drug sonidegib. Cisplatin is administered as a concentrate for infusion, lomustine is taken orally, and vincristine is given as an injection. The study will also involve a placebo group to help determine the effectiveness of the new treatment approach. The main goal is to see if the personalized treatment can help patients live longer without the cancer getting worse, which is known as progression-free survival.

The study will take place over several weeks, with regular monitoring and assessments to track the progress of the disease and any side effects of the treatment. Participants will undergo various tests, including MRI scans, to evaluate the tumor’s response to the treatment. The trial will also collect information on the overall survival of patients and any adverse events they may experience. Additionally, the study will assess the impact of the treatment on patients’ quality of life and cognitive functions. The trial is expected to continue until 2030, with the aim of providing valuable insights into the effectiveness of personalized treatment for medulloblastoma.

]]> Study on the Effectiveness of Bevacizumab and Drug Combination for Children with Recurrent or Progressive Medulloblastoma, Ependymoma, and ATRT https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-bevacizumab-and-drug-combination-for-children-with-recurrent-or-progressive-medulloblastoma-ependymoma-and-atrt/ Wed, 29 Apr 2026 14:23:16 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-bevacizumab-and-drug-combination-for-children-with-recurrent-or-progressive-medulloblastoma-ependymoma-and-atrt/ This clinical trial is focused on studying treatments for children with certain types of brain tumors, specifically medulloblastoma, ependymoma, and atypical teratoid rhabdoid tumor (ATRT). These are serious conditions where abnormal cells form in the tissues of the brain. The study aims to explore the effectiveness of a combination of medications that target the blood vessels that supply the tumor, a process known as anti-angiogenesis therapy. The medications being tested include Cytarabine, Celecoxib, Cyclophosphamide, Etoposide, Bevacizumab, Fenofibrate, and Thalidomide. Some of these medications are given as injections, while others are taken orally as capsules.

The purpose of the study is to determine how well these treatments work in stopping the growth of these tumors. Participants in the study will receive these medications over a period of time, and their health will be monitored closely by the research team. The study will look at how the tumors respond to the treatment, whether they shrink, stay the same, or grow, and how long the patients remain free of tumor growth. The study will also monitor the overall health and quality of life of the participants during and after the treatment.

Throughout the study, participants will receive regular check-ups and tests to track their progress. The research team will evaluate the safety and side effects of the treatments, ensuring that any adverse effects are managed promptly. The study is designed to gather important information that could lead to better treatment options for children with these challenging brain tumors in the future.

]]>